1 / 93

lactate

tCho. tCho. mI. mI. tCr. tCr. glx. glx. lactate. lactate. lipids. lipids. 4. 4. 3. 3. 2. 2. 1. 1. 0. 0. ppm. ppm. INTERPRET International Network for Pattern Recognition of Tumours using Resonance. “NOSOLOGIC” IMAGES FROM CSI.

durin
Télécharger la présentation

lactate

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. tCho tCho mI mI tCr tCr glx glx lactate lactate lipids lipids 4 4 3 3 2 2 1 1 0 0 ppm ppm INTERPRET International Network for Pattern Recognition of Tumours using Resonance

  2. “NOSOLOGIC” IMAGES FROM CSI

  3. FORESEEN RESULTS/PRODUCTS 1. Database of spectra, images, clinical data and CDVC-validated anatomy pathologies. 2. Combination of database structure, automated processing tools and GUI developped to store and display the MRS/MRI and clinical data. 3. The decission support tool. Incorporates 1, 2 and the classifiers developped by INTERPRET.

  4. WP1 Project management

  5. EU Comission Project Project Officer Management Committee Project Administrator Clinical Data Project Validation Co-cordinator Committee Quality Partner 2 Evaluators SGHMS (QAU-UAB) Scientific Project Manager Administrator External Advisory Evaluators Group WP1 - PM WP2 - DB WP6 - A&E WP3 - PR WP7 - D&I WP4 - GUI WP5 - IPCE WP8 - CP

  6. MANAGING TASKS FOR INTERPRET. • Internal/Regular reports • Communication with EU • Cost statements • Consortium Agreement • Meetings (plenary, PMC, CDVC, technical) • Communication within Consortium (e-mail lists, web pages, newsletter) • Deliverables

  7. REPORTS 12-month report: SENT 15-month report: SENT 18-month report: SENT 21-month report: being finalised Next report: 24-month report

  8. MANAGING TASKS FOR INTERPRET. • Internal/Regular reports • Communication with EU • Cost statements • Consortium Agreement • Meetings (plenary, PMC, CDVC, technical) • Communication within Consortium (e-mail lists, web pages, newsletter) • Deliverables

  9. COMMUNICATION WITH EU • Attendance to Annual Technical Reviews • Attendance to clustering meetings: • Clustering Telemedicine meeting on February 18th, 2000 • 1st Health Concertation Meeting for the 5th Frame Work programme (HCM 5th FP-01), Brussels, November, 20th, 2000 • Next one scheduled: 2nd cluster concertation meeting (Systems and Services for the Citizen, Applications relating to Health), Brussels, November 23rd, 2001 • Contract amendments: contract amendment for certification related issues submitted in June, 26th, 2001

  10. MANAGING TASKS FOR INTERPRET. • Internal/Regular reports • Communication with EU • Cost statements • Consortium Agreement • Meetings (plenary, PMC, CDVC, technical) • Communication within Consortium (e-mail lists, web pages, newsletter) • Deliverables

  11. COST STATEMENTS • 2nd Cost Statements: sent in August, 2001; corrections sent in September, 2001 • Next Cost Statements: June, 2002

  12. MANAGING TASKS FOR INTERPRET. • Internal/Regular reports • Communication with EU • Cost statements • Consortium Agreement • Meetings (plenary, PMC, CDVC, technical) • Communication within Consortium (e-mail lists, web pages, newsletter) • Deliverables

  13. CONSORTIUM AGREEMENT • The Consortium Agreement was agreed in March, 2001 and signed by all the INTERPRET partners • Based in the Unified Consortium Agreement for FP5 projects, vers:1.0 991010

  14. MANAGING TASKS FOR INTERPRET. • Internal/Regular reports • Communication with EU • Cost statements • Consortium Agreement • Meetings (plenary, PMC, CDVC, technical) • Communication within Consortium (e-mail lists, web pages, newsletter) • Deliverables

  15. MEETINGS • 3rd PMC meeting, teleconference, 19th December, 2000 • 4th PMC meeting, Grenoble, 1st February, 2001 • 5th PMC meeting, teleconference, 20th February, 2001 • 6th PMC meeting, teleconference, 14th March, 2001 • 7th PMC meeting, Barcelona, 6th June, 2001 • 8th PMC meeting, teleconference, 17th September, 2001 • 3rd CDVC meeting, Grenoble, 1st February, 2001 • 4th CDVC meeting, Barcelona, 5th June, 2001 • Technical meeting: WP 3 (Pattern Recognition) and WP 5 (Integration of prototypes and clinical evaluation), Grenoble, 1st-2nd February, 2001 • Technical meeting: Scientific Workshop and Pattern Recognition meeting, Barcelona, 6th-7th June, 2001 • Certification meeting between INTERPRET Consortium and Pharma Quality Europe (PQE), Barcelona, 5th June, 2001

  16. MANAGING TASKS FOR INTERPRET. • Internal/Regular reports • Communication with EU • Cost statements • Consortium Agreement • Meetings (plenary, PMC, CDVC, technical) • Communication within Consortium (e-mail lists, web pages, newsletter) • Deliverables

  17. COMMUNICATION WITHIN CONSORTIUM • Continuation of pre-existing e-mail lists: • interpret (general e-mail list) • interpret pm (WP 1: Project management) • interpret db (WP 2: Database development) • interpret pr (WP 3: Pattern Recognition) • interpret gui (WP4: GUI development) • interpret ae (WP 6: Assessment and evaluation) • interpret di (WP 7: Dissemination and Implementation) • interpret cp (WP 8: Certification of procedures) • interpret pmc (Project Management Committee) • interpret cdvc (Clinical Data Validation Committee) • interpret uos (Partner 8 e-mail list) • interpret user (list of people interested in helping develop the users interface) • 19 bi-weekly Newsletters edited and circulated to all members of INTERPRET. • Project websites: • http://carbon.uab.es/INTERPRET • http://cogs.susx.ac.uk/users/desw/interpret-mail • http://www.cogs.susx.ac.uk/users/joshuau/requirements_docs

  18. DOCUMENTS AT THE PRIVATE SITE OF THE INTERPRET WEB PAGE (http:carbon.uab.es/INTERPRET) • 10 TEMPLATES • 38 MEETING, PROJECT AND MANAGING REPORTS AND DOCUMENTS • 36 TECHNICAL REPORTS • 9 DELIVERABLES

  19. DOCUMENTS AT THE PRIVATE SITE OF THE INTERPRET WEB PAGE (http:carbon.uab.es/INTERPRET) • 10 TEMPLATES • 38 MEETING, PROJECT AND MANAGING REPORTS AND DOCUMENTS • 36 TECHNICAL REPORTS • 9 DELIVERABLES

  20. DOCUMENTS AT THE PRIVATE SITE OF THE INTERPRET WEB PAGE (http:carbon.uab.es/INTERPRET) • 10 TEMPLATES • 38 MEETING, PROJECT AND MANAGING REPORTS AND DOCUMENTS • 36 TECHNICAL REPORTS • 9 DELIVERABLES

  21. DOCUMENTS AT THE PRIVATE SITE OF THE INTERPRET WEB PAGE (http:carbon.uab.es/INTERPRET) • 10 TEMPLATES • 38 MEETING, PROJECT AND MANAGING REPORTS AND DOCUMENTS • 36 TECHNICAL REPORTS • 9 DELIVERABLES

  22. DOCUMENTS AT THE PRIVATE SITE OF THE INTERPRET WEB PAGE (http:carbon.uab.es/INTERPRET) • 10 TEMPLATES • 38 MEETING, PROJECT AND MANAGING REPORTS AND DOCUMENTS • 36 TECHNICAL REPORTS • 9 DELIVERABLES

  23. MANAGING TASKS FOR INTERPRET. • Internal/Regular reports • Communication with EU • Cost statements • Consortium Agreement • Meetings (plenary, PMC, CDVC, technical) • Communication within Consortium (e-mail lists, web pages, newsletter) • Deliverables

  24. DELIVERABLES

  25. WP2 DB Development

  26. TASK 2.13 Standardisation of histopathological diagnosis Status of the validation process. 177 patients with fully validated clinical data.

  27. Semiautomated quality control of spectra 1- PRELIMINARY DATABASE Task 2.8. Data releases to INTERPRET partners during present year.

  28. Task 2.8. Description of final contents of the ipDB. Numbers and sources of patients. Total: 388 patients.

  29. Task 2.8. Description of final contents of the ipDB. Patients broken by pathologies.

  30. SGHMS UJF FMW/AZN LODZ VALIDATION IDI 155 CDP 225 FLENI 8 83 11 ipDB INTERPRET DB VALIDATION Flow chart of patient incorporation into iDB

  31. Task 2.10. Application of quality control procedures to all incoming new patient data. ipDB: Semiautomated quality control approach for incoming spectra

  32. Semiautomated quality control approach 1

  33. Semiautomated quality control approach 2

  34. Semiautomated quality control approach 3

  35. Task 2.10Quality Control

  36. Ac 2.38 3.78 2.09 Ac 2.32 3.76 2.02 2.28 Choline 2.15 Ac 3.78 Creatine 3.77 2.34 2.33 2.05 2.03 2.16 Alanine 2.10 Phantom Studies • Studies of the phase modulations of some compounds (eg. Glutamate, glutamine); try to relate these changes wiht some tumoral types. • Calculation of glutamate/glutamine mean spectra (long echo time) • Try to coordinate the pattern recognition of some cerebral tumours with the phase modulation seen in presence of one, another or both compounds. Compare with real cases.

  37. 2- DEFINITIVE DATABASE Clinical Data Input • Access through the web, so accesible for providing centers and for validation. • Information can be input progresively as it becomes avaliable.

  38. Maintenance of MRS Resources • Basic maintenance form that allows to add, edit or remove resources.

  39. Maintenance of MRS Resources (detail 1) • Basic set of acquisition parameters for describing the spectrum. They can be both automatically or manually entered.

  40. Maintenance of MRS Resources (detail 2) • Possibility of storing and retreiving other parameters recognized by the system or defined by the user for other purposes as quality control.

  41. Maintenance of MRS Resources (detail 3) • Possibility of storing and retreaving additional resources such as processed data.

  42. Maintenance of MRS Resources (detail 4) • Simple file upload through web interface for adding resources.

  43. Data Retrieval (detail 1) • Flexible record filter specification for selection according to clinical record attributes and later download of corresponding data.

More Related